Wolfgang S.
- Country
- Germany
- Department
- Klinik für Innere Medizin II-Pneumologie
Research Overview
- Evaluation of Chemotherapy Addition in EGFR-Mutant Advanced NSCLC with Persistent Plasma ctDNA EGFR Mutation Post-Osimertinib Therapy
- Phase 2 Evaluation of Cemiplimab and BNT116 Combination Versus Cemiplimab Monotherapy in Advanced NSCLC with PD-L1 Expression ≥50%
- A Phase 3 Randomized Open-Label Study Comparing Sigvotatug Vedotin and Docetaxel in Adults with Previously Treated Non-Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 277 of 558 partner sites.
Specializations
Non-Small Cell Lung Cancer
The investigator is strongly involved in the treatment of non-small cell lung cancer, with attention to advanced, metastatic, unresectable, and resectable disease settings. Research activity spans biomarker-defined populations, including EGFR-mutated and KRAS G12C-mutated disease, as well as tumors with PD-L1 expression-based selection.
- Advanced and metastatic NSCLC
- EGFR-mutated NSCLC
- KRAS G12C-mutated NSCLC
- PD-L1-selected NSCLC
- Perioperative and neoadjuvant NSCLC treatment
Clinical interest also includes locally advanced disease after chemoradiation and early-stage lung cancer managed with surgery or radiotherapy.
Small-Cell Lung Cancer
The clinical portfolio includes substantial work in small-cell lung cancer, particularly extensive-stage small-cell lung cancer and relapsed disease. The focus is on treatment strategies that combine systemic therapy with immuno-oncology and supportive approaches in aggressive thoracic malignancy.
- Extensive-stage SCLC
- Relapsed SCLC
- First-line SCLC treatment
- Maintenance therapy in ES-SCLC
This area reflects sustained involvement in improving outcomes for high-risk lung cancer populations.
Genitourinary Oncology
Research activity extends to urothelial cancer, muscle-invasive bladder cancer, and renal cell carcinoma. The investigator is engaged in therapeutic development across perioperative, adjuvant, and metastatic settings, with emphasis on immune-based and targeted treatment options.
- Muscle-invasive bladder cancer
- Locally advanced or metastatic urothelial cancer
- Renal cell carcinoma
- Adjuvant and perioperative genitourinary therapy
Additional interest includes high-risk disease after surgery and treatment selection in advanced solid tumors of the urinary tract and kidney.
Respiratory and Inflammatory Disease
The investigator also contributes to clinical research in bronchiectasis and severe eosinophilic asthma, reflecting involvement in chronic respiratory disease management beyond oncology. These studies focus on patients with persistent airway inflammation and recurrent pulmonary symptoms.
- Bronchiectasis
- Severe asthma with an eosinophilic phenotype
- Chronic airway inflammation
Therapeutic interest in this area centers on long-term control of respiratory morbidity and exacerbation prevention.
Neurology and Acute Care
Research involvement includes selected studies in chronic inflammatory demyelinating polyneuropathy, secondary progressive multiple sclerosis, and acute ischemic stroke. This indicates engagement with immune-mediated neurologic disease and emergency vascular neurology.
- Chronic inflammatory demyelinating polyneuropathy
- Secondary progressive multiple sclerosis
- Acute ischemic stroke
The therapeutic scope in neurology spans relapse prevention, disability progression, and acute reperfusion-related care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.